Stigter-van Walsum M - Search Results

1

Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody.

Oliveira S, van Dongen GA, Stigter-van Walsum M, Roovers RC, Stam JC, Mali W, van Diest PJ, van Bergen en Henegouwen PM. Oliveira S, et al. Mol Imaging. 2012 Feb;11(1):33-46. Mol Imaging. 2012. PMID: 22418026

2

Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer.

van Gog FB, Brakenhoff RH, Stigter-van Walsum M, Snow GB, van Dongen GA. van Gog FB, et al. Int J Cancer. 1998 Jul 3;77(1):13-8. doi: 10.1002/(sici)1097-0215(19980703)77:1<13::aid-ijc3>3.0.co;2-2. Int J Cancer. 1998. PMID: 9639387

3

Characterization of CD44v6 isoforms in head-and-neck squamous-cell carcinoma.

van Hal NL, van Dongen GA, Stigter-van Walsum M, Snow GB, Brakenhoff RH. van Hal NL, et al. Int J Cancer. 1999 Sep 9;82(6):837-45. doi: 10.1002/(sici)1097-0215(19990909)82:6<837::aid-ijc12>3.0.co;2-h. Int J Cancer. 1999. PMID: 10446451

4

Characterization of the human Ly-6 antigens, the newly annotated member Ly-6K included, as molecular markers for head-and-neck squamous cell carcinoma.

de Nooij-van Dalen AG, van Dongen GA, Smeets SJ, Nieuwenhuis EJ, Stigter-van Walsum M, Snow GB, Brakenhoff RH. de Nooij-van Dalen AG, et al. Int J Cancer. 2003 Mar 1;103(6):768-74. doi: 10.1002/ijc.10903. Int J Cancer. 2003. PMID: 12516096

5

89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.

Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GA. Verel I, et al. J Nucl Med. 2003 Aug;44(8):1271-81. J Nucl Med. 2003. PMID: 12902418 Free article.

6

Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.

Verel I, Visser GW, Boerman OC, van Eerd JE, Finn R, Boellaard R, Vosjan MJ, Stigter-van Walsum M, Snow GB, van Dongen GA. Verel I, et al. Cancer Biother Radiopharm. 2003 Aug;18(4):655-61. doi: 10.1089/108497803322287745. Cancer Biother Radiopharm. 2003. PMID: 14503961

7

(89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.

Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, Leemans CR, van Dongen GA. Perk LR, et al. J Nucl Med. 2005 Nov;46(11):1898-906. J Nucl Med. 2005. PMID: 16269605 Free article.

8

Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.

Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA. Tijink BM, et al. J Nucl Med. 2006 Jul;47(7):1127-35. J Nucl Med. 2006. PMID: 16818947 Free article.

9

Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography.

Perk LR, Visser OJ, Stigter-van Walsum M, Vosjan MJ, Visser GW, Zijlstra JM, Huijgens PC, van Dongen GA. Perk LR, et al. Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1337-45. doi: 10.1007/s00259-006-0160-0. Epub 2006 Jul 11. Eur J Nucl Med Mol Imaging. 2006. PMID: 16832633

10

The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells.

van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, Moshaver B, Stigter-van Walsum M, Zweegman S, Ossenkoppele GJ, Jan Schuurhuis G. van Rhenen A, et al. Blood. 2007 Oct 1;110(7):2659-66. doi: 10.1182/blood-2007-03-083048. Epub 2007 Jul 3. Blood. 2007. PMID: 17609428 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters